June 19, 2019

Research Highlights Long-Term Efficacy of PCSK9 Inhibitor

By Jennifer Barrett, Associate Editor
Published Online: Tuesday, Dec 11, 2018

According to the findings, investigators concluded that LLTs were underused among patients at high risk for cardiovascular events—those with LDL-C levels ≥70 mg/dL. The analysis showed that support for high-intensity statins and PCSK9 inhibitor use was at 75% among physicians, but the actual observed use was 50% and 10%, respectively. Additionally, physicians cited cost and hassle associated with prior authorization requirements as reasons for not prescribing. Among patients receiving LLT, more than 70% did not know the main goal of this treatment and nearly half were unaware of their total lipid levels, highlighting an educational gap. Data also showed that a large proportion of patients were unaware of their ASCVD risk, LDL-C levels, or therapy goals.

Despite the efficacy of PCSK9 inhibitors, the high cost of these medications can cause barriers to access. In October, Amgen announced it was reducing the price of evolocumab by 60% from its annual list price of $14,100. The manufacturer will continue to offer evolocumab at its original price, but is expected to discontinue the original cost by the end of 2020 or sooner.

These analyses were presented at the American Heart Association’s Scientific Sessions 2018 in Chicago.

Reference

Amgen Presents Results Highlighting The Long-Term Safety and Efficacy of Repatha® (Evolocumab) In The Longest Duration Study Of A PCSK9 Inhibitor To Date At AHA Scientific Sessions 2018 [news release]. Amgen’s website. https://www.amgen.com/media/news-releases/2018/11/amgen-presents-results-highlighting-the-longterm-safety-and-efficacy-of-repatha-evolocumab-in-the-longest-duration-study-of-a-pcsk9-inhibitor-to-date-at-aha-scientific-sessions-2018/. Accessed November 16, 2018.

About the Specialty Pharmacy Times Industry Guide

The Specialty Pharmacy Times Industry Guide includes comprehensive editorial content relative to all specialty pharmacy stakeholders. Content includes information relative to market trends, commercialization, distribution, order to cash, HUB Services, managed care strategies and DIR fees. The guide also includes profiles, and a complete list of stakeholders along the patient journey: specialty pharmacies, wholesaler distributors, manufacturers, support services, group purchasing, and trade associations.

Sign Up for the Industry Guide Newsletter

Copyright © 2006-2018 Pharmacy & Healthcare Communications, LLC
All Rights Reserved

About Us